Cost-effectiveness of human papillomavirus vaccination in Germany

Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W (2017)
Cost Effectiveness and Resource Allocation 15: 18.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 1.03 MB
Autor/in
; ; ; ; ; ; ; ; ;
Abstract / Bemerkung
Background The aim of this study was to assess the cost-effectiveness of human papillomavirus (HPV) vaccination in addition to the current cervical cancer screening programme in Germany using a dynamic transmission model. Methods Based on a mathematical model simulating the transmission dynamics and the natural history of HPV infection and associated diseases (cervical intraepithelial neoplasia, cervical cancer, and genital warts), we estimated the epidemiological and economic consequences of HPV vaccination with both the quadrivalent and bivalent vaccines. In our base case analysis, we assessed the cost-effectiveness of vaccinating 12-year-old girls with a 3-dose schedule. In sensitivity analysis, we also evaluated the use of a 2-dose schedule and assessed the impact of vaccinating boys. Results From a health care payer perspective, incremental cost-effectiveness ratios (ICERs) of a 3-dose schedule were €34,249 per quality-adjusted life year (QALY) for the bivalent and €14,711 per QALY for the quadrivalent vaccine. Inclusion of indirect costs decreased ICERs by up to 40%. When adopting a health care payer perspective, ICERs of a 2-dose approach decreased to €19,450 per QALY for the bivalent and to €3645 per QALY for the quadrivalent vaccine. From a societal perspective, a 2-dose approach using the quadrivalent vaccine was a cost-saving strategy while using the bivalent vaccine resulted in an ICER of €13,248 per QALY. Irrespective of the perspective adopted, additional vaccination of boys resulted in ICERs exceeding €50,000 per QALY, except for scenarios with low coverage (20%) in girls. Conclusions Our model results suggest that routine HPV vaccination of 12-year-old girls with three doses is likely to be cost-effective in Germany. Due to the additional impact on genital warts, the quadrivalent vaccine appeared to be more cost-effective than the bivalent vaccine. A 2-dose schedule of the quadrivalent vaccine might even lead to cost savings when adopting a societal perspective. The cost-effectiveness of additional vaccination of boys was highly dependent on the coverage in girls.
Stichworte
HPV Vaccination Economic evaluation Cost-effectiveness Dynamic transmission model Germany
Erscheinungsjahr
2017
Zeitschriftentitel
Cost Effectiveness and Resource Allocation
Band
15
Art.-Nr.
18
ISSN
1478-7547
Finanzierungs-Informationen
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of Bielefeld University.
Page URI
https://pub.uni-bielefeld.de/record/2914076

Zitieren

Damm O, Horn J, Mikolajczyk RT, et al. Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation. 2017;15: 18.
Damm, O., Horn, J., Mikolajczyk, R. T., Kretzschmar, M. E. E., Kaufmann, A. M., Deleré, Y., Ultsch, B., et al. (2017). Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation, 15, 18. doi:10.1186/s12962-017-0080-9
Damm, O., Horn, J., Mikolajczyk, R. T., Kretzschmar, M. E. E., Kaufmann, A. M., Deleré, Y., Ultsch, B., Wichmann, O., Krämer, A., and Greiner, W. (2017). Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation 15:18.
Damm, O., et al., 2017. Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation, 15: 18.
O. Damm, et al., “Cost-effectiveness of human papillomavirus vaccination in Germany”, Cost Effectiveness and Resource Allocation, vol. 15, 2017, : 18.
Damm, O., Horn, J., Mikolajczyk, R.T., Kretzschmar, M.E.E., Kaufmann, A.M., Deleré, Y., Ultsch, B., Wichmann, O., Krämer, A., Greiner, W.: Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation. 15, : 18 (2017).
Damm, Oliver, Horn, Johannes, Mikolajczyk, Rafael T., Kretzschmar, Mirjam E. E., Kaufmann, Andreas M., Deleré, Yvonne, Ultsch, Bernhard, Wichmann, Ole, Krämer, Alexander, and Greiner, Wolfgang. “Cost-effectiveness of human papillomavirus vaccination in Germany”. Cost Effectiveness and Resource Allocation 15 (2017): 18.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
This Item is protected by copyright and/or related rights. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-09-06T09:18:52Z
MD5 Prüfsumme
2050c886488ea0fe1d5881031aa4667a

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 28878573
PubMed | Europe PMC

Suchen in

Google Scholar